EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars
About author
You might also like
Philips introduces new diagnostic device to prevent childhood pneumonia
Royal Philips has announced the upcoming release of a Children’s Automated Respiration Monitor, aimed to help improve the diagnosis and treatment of pneumonia in low-resource countries, potentially preventing many of
Aspirin may halve air pollution harms
A new study has revealed evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function. This findings were published in
Fidson Pharma rewards Astymin users
… Rolls out cash promo Users of Astymin brand of multivitamin, will now gain financial and nutritional reward through constant use of the multivitamin. Makers of the brand, Fidson Pharmaceuticals
0 Comments
No Comments Yet!
You can be first to comment this post!